How Waters wants AI to take the grunt work out of drug testing Waters took one-and-a-half years to develop its new AI tool, which it says will cut manual drug-testing work performed by scientists by 95%. Fortune · Oct 28
One Recalled Saline Ampule Set Off a Cascade of Kit Recalls Reaching Thousands of American Hospitals FDA has posted a run of early alerts and recalls involving convenience kits, most tracing back to recalled drug ampules and syringes. Medical Daily · Aug 26
Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal Becton Dickinson and Co (NYSE:BDX) reported fourth-quarter adjusted earnings of $3.96, beating the consensus of $3.92. Benzinga · Nov 6, 2025
Becton, Dickinson and Company Stock: Is Wall Street Bullish or Bearish? Despite Becton, Dickinson and Company’s weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects. Barchart · Aug 18, 2025
Becton Dickinson Q3 Beats Estimates On Medical Device Boom As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company (NYSE:BDX) are reporting robust financial performances that highlight their resilience and strategic adaptability. The company’s stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings. Benzinga · Aug 7, 2025
3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential. Barchart · Jul 19, 2024
Stocks Settle Mixed as 10-Year T-note Yield Stays Above 4% What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for... Barchart · Jan 9, 2024
Becton Dickinson & Co. (BDX) Earnings Moves: A Buy or Sell for Investors? Becton Dickinson & Co. (BDX) is expected to report steady growth for its fiscal fourth quarter ended September 2023, scheduled to be released on November 9. While the stock is witnessing weakness over the past month, will the quarterly report be able to spur a rally? Read on. StockNews.com · Nov 8, 2023
What Are Whales Doing With Becton, Dickinson Someone with a lot of money to spend has taken a bearish stance on Becton, Dickinson (NYSE:BDX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Sep 1, 2022
Death Cross Looms Over Becton, Dickinson Investors If history is any guide, there may be trouble ahead for shares of Becton, Dickinson (NYSE:BDX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. Benzinga · Jul 6, 2022
Looking Into Becton, Dickinson's Recent Short Interest Becton, Dickinson's (NYSE:BDX) short percent of float has fallen 9.33% since its last report. The company recently reported that it has 3.87 million shares sold short, which is 1.36% of all regular shares that are available for trading. Benzinga · Jun 28, 2022
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,400 Today Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.98% on an annualized basis producing an average annual return of 12.93%. Currently, Becton, Dickinson has a market capitalization of $70.95 billion. Benzinga · Jun 27, 2022
Analyst Ratings for Becton, Dickinson Within the last quarter, Becton, Dickinson (NYSE:BDX) has observed the following analyst ratings: Benzinga · Jun 24, 2022
Benzinga · Jun 10, 2022 Analyzing Becton, Dickinson's Short Interest Becton, Dickinson's (NYSE:BDX) short percent of float has risen 11.94% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 1.5% of all regular shares that are available for trading.
Benzinga · Jun 9, 2022 Here's How Much You Would Have Made Owning Becton, Dickinson Stock In The Last 20 Years Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.34% on an annualized basis producing an average annual return of 10.37%. Currently, Becton, Dickinson has a market capitalization of $71.95 billion.
Benzinga · Jun 6, 2022 Becton Dickinson Buying Parata Systems - Read Why Becton Dickinson and Co (NYSE:BDX) will acquire Parata Systems from Frazier Healthcare Partners for $1.525 billion. Parata offers a portfolio of pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience. Significant macro trends such as clinician shortages, wage inflation, centralization of pharmacy services, and increased clinical demands…
Benzinga · May 27, 2022 $1000 Invested In Becton, Dickinson 10 Years Ago Would Be Worth This Much Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.48% on an annualized basis producing an average annual return of 13.59%. Currently, Becton, Dickinson has a market capitalization of $72.68 billion.
StockNews.com · May 25, 2022 Better Buy: Becton Dickinson vs. Intuitive Surgical Growing demand for critical surgical procedures and increasing investments in R&D should drive the medical devices industry’s growth. Prominent medical device companies Becton Dickinson (BDX) and Intuitive Surgical (ISRG) are well-positioned to capitalize on the industry tailwinds. But which of these stocks is a better buy now? Read more to…
Benzinga · May 6, 2022 Expert Ratings for Becton, Dickinson Over the past 3 months, 5 analysts have published their opinion on Becton, Dickinson (NYSE:BDX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga · May 5, 2022 Becton Dickinson Raises FY22 Guidance As Q2 Earnings Top Estimates Becton Dickinson and Co (NYSE:BDX) reported Q2 FY22 revenues of $5.01 billion, up 2.1% Y/Y (3.9% on a currency-neutral basis), better than the consensus of $4.85 billion. Revenue was driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by the decline in COVID-only testing revenues to $214 million…
Benzinga · May 5, 2022 Becton, Dickinson: Q2 Earnings Insights Becton, Dickinson (NYSE:BDX) reported its Q2 earnings results on Thursday, May 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Benzinga · Mar 28, 2022 Expert Ratings For Becton, Dickinson Analysts have provided the following ratings for Becton, Dickinson (NYSE:BDX) within the last quarter:
StockNews.com · Jan 31, 2022 Baxter International vs. Becton Dickinson: Which Medical Equipment & Supply Stock is a Better Buy? The demand for medical equipment & supplies is rising exponentially with the emergence of severe illnesses such as the ongoing Coronavirus pandemic and the growing elderly population. So, Baxter International (BAX) and Becton Dickinson and Company (BDX) should benefit. But which of these two stocks is a better buy now?…